a-PPP
Well-documented
Well-documented
Multiple authoritative sources agree on dosing and effects.
- 4 corroborating sources
- 5 ROAs with full dose ladders
- duration data present
- 18 combo interactions documented
- classified Research-chemical
- 4 corroborating sources
- 5 ROAs with full dose ladders
- duration data present
- 18 combo interactions documented
- classified Research-chemical
Aliases: Ppp
Summary
Ξ±-PPP is the three-carbon homologue in the pyrrolidinophenone series (shorter alkyl chain than Ξ±-PVP and Ξ±-PBP). It acts as a potent DAT and NET inhibitor with negligible SERT activity, but uniquely also functions as a partial norepinephrine releasing agent and 5-HT2A antagonistβproperties not shared by Ξ±-PVP. This 5-HT2A antagonism may contribute to its reportedly lower euphoria and reduced popularity compared to Ξ±-PVP.
Dose Information
Dose basis. Ranges reflect aggregated user reports; large interindividual variability; salt form vs. freebase and tolerance materially alter potency. Start at the low end with an accurate milligram scale. Similar to oral but with slightly faster onset; bitterness and local irritation reported. (Dose figures and this note are from Drugs.Wiki.)
| ROA | Light | Common | Strong | Heavy |
|---|---|---|---|---|
| Oral | 15-30mg | 30-60mg | 60-90mg | 90mg+ |
| Sublingual | 15-30mg | 30-50mg | 50-80mg | 80mg+ |
| Insufflated | 10-20mg | 20-40mg | 40-70mg | 70mg+ |
| Vaporized | 5-10mg | 10-25mg | 25-40mg | 40mg+ |
| Intravenous | 25-50mg | 50-100mg | 100-150mg | 150mg+ |
Onset, Duration & After-effects
| ROA | Onset | Comeup | Peak | Offset | Total |
|---|---|---|---|---|---|
| Oral | 2 min | 2 min | 2 hrs | 2 hrs | 2 hrs |
| Sublingual | 15-30 min | 45-90 min | 4-6 hrs | 3-4 hrs | 8-12 hrs |
| Insufflated | 5-15 min | 10-20 min | 30 min | 1-2 hrs | 1.75-3.08 hrs |
| Vaporized | 1-2 min | 3-5 min | 30 min | 1-2 hrs | 1.57-2.61 hrs |
| Intravenous | 36 sec | 1-3 min | 30 min | 1-2 hrs | 1.53-2.56 hrs |
Effect Profile
Scores (1–10) curated from multiple sources:
- Effect keyword matching from PsychonautWiki catalog
- Weighted by importance: core (×3), major (×2), minor (×1)
Strong anxiety/jitters with moderate euphoria and focus, mild stimulation
Add to PsychonautWiki Journal
The PsychonautWiki Journal logging app doesn't include every substance. To track a-PPP there, start adding an ingestion, search for the name, and choose to add it as a custom substance. Paste these values:
a-PPP Source: SubstanceSearch (substancesearch.com) Oral dose (mg): threshold 10 Β· light 15-30 Β· common 30-60 Β· strong 60-90 Β· heavy 90+ Sublingual dose (mg): threshold 10 Β· light 15-30 Β· common 30-50 Β· strong 50-80 Β· heavy 80+ Insufflated dose (mg): threshold 5 Β· light 10-20 Β· common 20-40 Β· strong 40-70 Β· heavy 70+ Vaporized dose (mg): threshold 3 Β· light 5-10 Β· common 10-25 Β· strong 25-40 Β· heavy 40+ Intravenous dose (mg): threshold 20 Β· light 25-50 Β· common 50-100 Β· strong 100-150 Β· heavy 150+ Oral duration: onset 2m Β· come-up 2m Β· peak 2h Β· offset 2h Β· total 2h Β· after-effects 2h Sublingual duration: onset 15-30m Β· come-up 0.75-1.5h Β· peak 4-6h Β· offset 3-4h Β· total 8-12h Β· after-effects 12-48h Insufflated duration: onset 5-15m Β· come-up 10-20m Β· peak 30m Β· offset 1-2h Β· total 1.75-3.08h Β· after-effects 2-12h Vaporized duration: onset 1-2m Β· come-up 3-5m Β· peak 30m Β· offset 1-2h Β· total 1.57-2.61h Β· after-effects 2-12h Intravenous duration: onset 36s Β· come-up 1-3m Β· peak 30m Β· offset 1-2h Β· total 1.53-2.56h Β· after-effects 2-12h Note: ranges are harm-reduction guidance, not a prescription. Start low, go slow, and test your substances.
Tip: for quicker logging you can also add a Custom Unit in the app, e.g. common dose ~ 45 mg (Oral).
The app keeps custom substances simple, so the full dose ranges live in the description text above. Ranges are harm-reduction guidance, not a prescription.
Tolerance
Tolerance Decay
Acute tolerance: develops within a single session β the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Pattern based on user reports for shortβacting pyrrolidinophenones; high interindividual variability. Conservative spacing of sessions (β₯7 days) reduces escalation and crash severity.
Cross-Tolerances
Effects
- Stimulation
- Vasoconstriction
- Bruxism
- Tachycardia
- Temperature regulation suppression
- Increased heart rate
- Teeth grinding
- Insomnia
- Increased blood pressure
- Increased perspiration
- Focus enhancement
- Motivation enhancement
- Increased sociability
- Wakefulness
- Euphoria
- Cognitive euphoria
- Anxiety
- Compulsive redosing
- Paranoia
- Thought acceleration
- Increased libido
- Tactile enhancement
- Increased music appreciation
- Appetite suppression
- Light sensitivity
- Dehydration
- Disinhibition
- Vibrating vision
- Increase sexuality
Combinations
Cross-Check a-PPP with another substanceHelpful Links
Report an issue or suggest an edit
Spotted incorrect or dangerous information, have a correction, a new study, or a useful addition for a-PPP? Let us know. Reports are reviewed by moderators — this is not posted publicly.